Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.38 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.38 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.38 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PRNP | P04156 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4780465 | 0.85 | HTR2A (0.39) | ACHEL3MBTL1NPC1TDP1KMT2A | |
| SCHEMBL1432110 | 0.83 | ACHE (0.59) | MRGPRX4HDAC1HDAC6ACHETDP1 | |
| SCHEMBL4805336 | 0.82 | CES2 (0.43) | NPC1KMT2AHTTRAB9AGAA | |
| SCHEMBL31126239 | 0.82 | CES2 (0.43) | NPC1KMT2AHTTRAB9AGAA | |
| SCHEMBL3833650 | 0.82 | L3MBTL1 (0.53) | ACHEL3MBTL1NPC1TDP1KMT2A | |
| SCHEMBL27565314 | 0.81 | KMT2A (0.52) | MRGPRX4HDAC1HDAC6ACHESLC6A3 | |
| SCHEMBL14870776 | 0.80 | HDAC1 (0.46) | MRGPRX4HDAC1HDAC6ACHESLC6A3 | |
| SCHEMBL23819693 | 0.79 | CHRNA3 (0.50) | KCNQ3KCNQ2KCNE1KCNQ1TDP1 | |
| SCHEMBL3880440 | 0.79 | SMN1; SMN2 (0.43) | ACHEL3MBTL1NPC1TDP1KMT2A | |
| SCHEMBL18869516 | 0.79 | THRB (0.46) | MRGPRX4HDAC1HDAC6ACHESLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579479-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579479-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579479-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| EP-1218361-B1 | OXA- AND THIAZOLE DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2009-01-07 | — | — | EP | disclosed |
| EP-1218361-B1 | OXA- AND THIAZOLE DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2009-01-07 | — | — | EP | disclosed |
| EP-1939188-A1 | Oxa-and thiazole derivatives useful as antidiabetic and antiobesity agents | Bristol-Myers Squibb Company (US) | 2008-07-02 | — | — | EP | disclosed |
| EP-1939188-A1 | Oxa-and thiazole derivatives useful as antidiabetic and antiobesity agents | Bristol-Myers Squibb Company (US) | 2008-07-02 | — | — | EP | disclosed |
| US-20080009534-A1 | SUBSTITUTED ACID DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-10 | — | — | US | disclosed |
| WO-2008006044-A2 | SUBSTITUTED ACID DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008006044-A2 | SUBSTITUTED ACID DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-10 | — | — | WO | disclosed |
| US-20040171644-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T (US) | 2004-09-02 | — | — | US | disclosed |
| US-20040147560-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T | 2004-07-29 | — | — | US | disclosed |
| US-6727271-B2 | OXAZOLE OR THIAZOLE DERIVATIVES; ANTILIPEMIC AGENTS, HYPOTENSIVES, ANTINEOPLASTIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-27 | — | — | US | disclosed |
| US-6653314-B2 | Modulate blood glucose levels, triglyceride levels, insulin levels and non-esterified fatty acid levels | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-25 | — | — | US | disclosed |
| US-20030096846-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T (US) | 2003-05-22 | — | — | US | disclosed |
| US-20030087935-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T (US) | 2003-05-08 | — | — | US | disclosed |
| US-20030069275-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T (US) | 2003-04-10 | — | — | US | disclosed |
| EP-1218361-A1 | OXA- AND THIAZOLE DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-07-03 | — | — | EP | disclosed |
| US-6414002-B1 | ANTILIPEMIC AGENTS; ANTICANCER, ANTITUMOR AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2002-07-02 | — | — | US | disclosed |
| WO-2001021602-A1 | OXA- AND THIAZOLE DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069275-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | GPR119, LIPC, PNLIP | MRGPRX4 1881/4885HDAC1 276/4885HDAC6 364/4885 |
| US-20040147560-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | GPR119, LIPC, PNLIP | MRGPRX4 2066/4885HDAC1 250/4885HDAC6 353/4885 |
| US-20030096846-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | GPR119, LIPC, PNLIP | MRGPRX4 1881/4885HDAC1 276/4885HDAC6 364/4885 |
| US-20030087935-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | GPR119, LIPC, PNLIP | MRGPRX4 1881/4885HDAC1 276/4885HDAC6 364/4885 |
| US-20040171644-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | GPR119, LIPC, PNLIP | MRGPRX4 1881/4885HDAC1 276/4885HDAC6 364/4885 |
| US-20080009534-A1 | SUBSTITUTED ACID DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | GPR119, LIPC, CEL | MRGPRX4 1066/4885HDAC1 258/4885HDAC6 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.